In this article, we will explore the topic of NS-2710 in depth. From its origins to its relevance today, we will analyze different aspects that will allow us to understand the importance of NS-2710 in different contexts. With a multidisciplinary approach, we will address both historical and contemporary aspects, as well as their influence in areas such as culture, society and technology. Throughout these pages, we will seek to discover new perspectives and reflect on the significance of NS-2710 in today's world.
Identifiers | |
---|---|
| |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C22H20N4O |
Molar mass | 356.429 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
NS-2710 (LS-193,970) is an anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company NeuroSearch. It has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. NS-2710 is a potent but non-selective partial agonist at GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has anxiolytic effects comparable to chlordiazepoxide, and while it is a less potent anticonvulsant than the related drug NS-2664, it has a much longer duration of action, and similarly to other α2/α3-preferring partial agonists produces little sedative effects or physical dependence.